[A14-25] Eribulin (new therapeutic indication) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Last updated 03.11.2014
Project no.:
A14-25
Commission:
Commission awarded on 29.07.2014 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A16-31 | Eribulin (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A14-47 | Eribulin (Addendum to Commission A14-25) | Commission completed |
| A11-26 | Eribulin - Benefit assessment according to § 35a Social Code Book V (dossier assessment) | Commission completed |
Federal Joint Committee (G-BA)
2015-01-22 A G-BA decision was published.